OCA
TVTX icon

Octagon Capital Advisors’s Travere Therapeutics TVTX Stock Holding History

Octagon Capital Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-495,000
Closed -$6.98M – 46
2023
Q2 		$7.6M Hold
495,000
– – 1.06% 20
2023
Q1 		$11.1M Buy
+495,000
New +$10.5M 1.6% 14

Other funds holding TVTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Octagon Capital Advisors's TVTX Position: Q3 2023 in Review

Octagon Capital Advisors sold out of Travere Therapeutics (TVTX) in Q3 2023, closing a stake of 495,000 shares — an estimated $6.98M sold.

Octagon Capital Advisors first reported a position in TVTX in Q1 2023 and held it in 2 quarters. The position peaked at $11.1M in Q1 2023. 169 funds tracked by Wall St. Rank hold TVTX as of Q3 2023.

  • Octagon Capital Advisors reported no remaining Travere Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 495,000 Travere Therapeutics shares in Q3 2023, an estimated $6.98M.
  • Octagon Capital Advisors first reported a position in Travere Therapeutics in Q1 2023 and held it in 2 quarters.
  • Octagon Capital Advisors's Travere Therapeutics position peaked at $11.1M in Q1 2023.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2023.

Based on Octagon Capital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.